Table 1.
Demographics and disease characteristics of the patients at baseline (intention to treat population).
| Characteristic* | Xacrel (N = 85) | Ocrevus (N = 85) |
|---|---|---|
| Age, year | 33.14 ± 7.22 | 31.12 ± 7.27 |
| Female sex, no. (%) | 64 (75.29) | 67 (78.82) |
| No. of relapses in previous 12 month | 1.16 ± 0.43 | 1.13 ± 0.37 |
| Previous disease-modifying therapy, no./total no. (%)§ | 56 (65.88) | 63 (74.12) |
| No medication | 27 (31.76) | 21 (24.71) |
| Interferons | 25 (29.41) | 33 (38.82) |
| Fingolimod | 15 (17.65) | 13 (15.29) |
| Dimethyl fumarate | 10 (11.76) | 11 (12.94) |
| Glatiramer acetate | 8 (9.41) | 7 (8.24) |
| Mean EDSS score | 2.35 ± 1.01 | 2.18 ± 1.13 |
| Baseline values related to MRI assessment** | ||
| No. of gadolinium-enhancing lesions on T1-weighted MRI, no./total no. (%) | ||
| 0 | 60/77 (77.92) | 56/76 (73.70) |
| 1 | 9/77 (11.70) | 13/76 (17.11) |
| 2 | 3/77 (3.90) | 3/76 (3.95) |
| 3 | 2/77 (2.60) | 3/76 (3.95) |
| ≥ 4 | 3/77 (3.90) | 1/76 (1.32) |
| No. of lesions on T2-weighted MRI | 27.32 ± 20.32 | 27.33 ± 20.90 |
| Volume of lesions on T2-weighted MRI (cm3) | 11.81 ± 12.92 | 9.37 ± 10.10 |
EDSS expanded disability status scale, MRI magnetic resonance imaging.
*Plus-minus values are means ± SD.
**Information related to MRI assessment was not available for 17 patients (8 patients in the Xacrel and 9 patients in the Ocrevus).
§Data on previous treatment were collected only one year before the screening. Patients could be counted in several categories.